Introduction: Oxaliplatin is a platinum-derivative chemotherapeutic agent used in digestive tumours, in the adjuvant and metastatic setting. Oxaliplatin can cause a chronic peripheral sensory neuropathy which impacts the quality of life and is dose limiting. To date, no therapeutic strategies have proved effective in the treatment of oxaliplatin-induced peripheral neuropathy (OIPN). Methods: A computerized search of the literature on PubMed database was performed. Publisher original articles were included if they focused on treatment of peripheral neuropathy among patients submitted to oxaliplatin. Eleven out of 242 reviewed papers met our inclusion criteria and were subjected to a 19-item quality checklist. Results: The included studies differed with respect to study design, patient population and sample size, neuropathic symptoms assessment and efficacy measure. Most studies had an adequate quality. Ten trials tested one drug, and one pilot study tested a non-pharmacological treatment — the neurofeedback. Of these, 3 trials included only patients submitted to oxaliplatin-based chemotherapy. Duloxetine showed moderate efficacy in 3 trials. Topical treatment with capsaicin or 10% amitriptyline was promisors in 2 single-arm trials with a few sample s . Conclusion: In the last decade, there wasn ’ t an improvement in the treatment of chronic OIPN. The duloxetine is the unique drug with moderate efficacy on the treatment of OIPN. There is insufficient evidence to support a recommendation for any other treatment.
KeywordsPeripheral NeuropathyOxaliplatinChemotherapy-Induced Peripheral NeuropathyPainNeurotoxicitySupportive Care
Capdevila, J., Elez, E., Peralta, S., Macarulla, T., Ramos, F.J. and Tabernero, J. (2008) Oxaliplatin-Based Chemotherapy in the Management of Colorectal Cancer. Expert Review of Anticancer Therapy, 8, 1223-1236. https://doi.org/10.1586/14737140.8.8.1223
Argyriou, A.A., Polychronopoulos, P., Iconomou, G., Chroni, E. and Kalofonos, H.P. (2008) A Review on Oxaliplatin-Induced Peripheral Nerve Damage. Cancer Treatment Reviews, 34, 368-377. https://doi.org/10.1016/j.ctrv.2008.01.003
Sereno, M., et al. (2014) Oxaliplatin Induced-Neuropathy in Digestive Tumors. Critical Reviews in Oncology/Hematology, 89, 166-178. https://doi.org/10.1016/j.critrevonc.2013.08.009
Saif, M.W. and Reardon, J. (2005) Management of Oxaliplatin-Induced Peripheral Neuropathy. Therapeutics and Clinical Risk Management, 1, 249-258.
Cersosimo, R.J. (2005) Oxaliplatin-Associated Neuropathy: A Review. Annals of Pharmacotherapy, 39, 128-135. https://doi.org/10.1345/aph.1E319
Pasetto, L.M., D’Andrea, M.R., Rossi, E. and Monfardini, S. (2006) Oxaliplatin-Related Neurotoxicity: How and Why? Critical Reviews in Oncology/Hematology, 59, 159-168. https://doi.org/10.1016/j.critrevonc.2006.01.001
Bennett, B.K., Park, S.B., Lin, C.S., Friedlander, M.L., Kiernan, M.C. and Goldstein, D. (2012) Impact of Oxaliplatin-Induced Neuropathy: A Patient Perspective. Support Care Cancer, 20, 2959-2967. https://doi.org/10.1007/s00520-012-1428-5
Beijers, A.J., Mols, F. and Vreugdenhil, G. (2014) A Systematic Review on Chronic Oxaliplatin-Induced Peripheral Neuropathy and the Relation with Oxaliplatin Administration. Support Care Cancer, 22, 1999-2007. https://doi.org/10.1007/s00520-014-2242-z
Mols, F., Beijers, T., Vreugdenhil, G. and van de Poll-Franse, L. (2014) Chemotherapy-Induced Peripheral Neuropathy and Its Association with Quality of Life: A Systematic Review. Support Care Cancer, 22, 2261-2269. https://doi.org/10.1007/s00520-014-2255-7
Pulvers, J.N. and Marx, G. (2017) Factors Associated with the Development and Severity of Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review. Asia-Pacific Journal of Clinical Oncology, 13, 345-355. https://doi.org/10.1111/ajco.12694
Derksen, T.M., Bours, M.J., Mols, F. and Weijenberg, M.P. (2017) Lifestyle-Related Factors in the Self-Management of Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer: A Systematic Review. Evidence-Based Complementary and Alternative Medicine, 2017, Article ID: 7916031. https://doi.org/10.1155/2017/7916031
Jordan, B., Jahn, F., Beckmann, J., Unverzagt, S., Müller-Tidow, C. and Jordan, K. (2016) Calcium and Magnesium Infusions for the Prevention of Oxaliplatin-Induced Peripheral Neurotoxicity: A Systematic Review. Oncology, 90, 299-306. https://doi.org/10.1159/000445977
Zajaczkowska, R., Kocot-Kepska, M., Leppert, W., Wrzosek, A., Mika, J. and Wordliczek, J. (2019) Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. International Journal of Molecular Sciences, 20, 1451. https://doi.org/10.3390/ijms20061451
Starobova, H. and Vetter, I. (2017) Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. Frontiers in Molecular Neuroscience, 10, 174. https://doi.org/10.3389/fnmol.2017.00174
Hershman, D.L., et al. (2014) Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 32, 1941-1967.
Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G. and Group, P. (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Journal of Clinical Epidemiology, 62, 1006-1012. https://doi.org/10.1016/j.jclinepi.2009.06.005
Schulz, K.F., Altman, D.G. and Moher, D. (2010) CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. Journal of Pharmacology & Pharmacotherapeutics, 1, 100-107. https://doi.org/10.4103/0976-500X.72352
Yang, Y.H., et al. (2012) Duloxetine Improves Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer: An Open-Label Pilot Study. Support Care Cancer, 20, 1491-1497. https://doi.org/10.1007/s00520-011-1237-2
Smith, E.M., et al. (2013) Effect of Duloxetine on Pain, Function, and Quality of Life among Patients with Chemotherapy-Induced Painful Peripheral Neuropathy: A Randomized Clinical Trial. JAMA, 309, 1359-1367.
Hirayama, Y., et al. (2015) Effect of Duloxetine in Japanese Patients with Chemotherapy-Induced Peripheral Neuropathy: A Pilot Randomized Trial. International Journal of Clinical Oncology, 20, 866-871. https://doi.org/10.1007/s10147-015-0810-y
Prinsloo, S., et al. (2017) Randomized Controlled Trial of Neurofeedback on Chemotherapy-Induced Peripheral Neuropathy: A Pilot Study. Cancer, 123, 1989-1997. https://doi.org/10.1002/cncr.30649
Filipczak-Bryniarska, I., et al. (2017) High-Dose 8% Capsaicin Patch in Treatment of Chemotherapy-Induced Peripheral Neuropathy: Single-Center Experience. Medical Oncology, 34, 162. https://doi.org/10.1007/s12032-017-1015-1
Rossignol, J., et al. (2019) High Concentration of Topical Amitriptyline for Treating Chemotherapy-Induced Neuropathies. Support Care Cancer, 27, 3053-3059. https://doi.org/10.1007/s00520-018-4618-y
Rao, R.D., et al. (2007) Efficacy of Gabapentin in the Management of Chemotherapy-Induced Peripheral Neuropathy: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Crossover Trial (N00C3). Cancer, 110, 2110-2118. https://doi.org/10.1002/cncr.23008
Saif, M.W., Syrigos, K., Kaley, K. and Isufi, I. (2010) Role of Pregabalin in Treatment of Oxaliplatin-Induced Sensory Neuropathy. Anticancer Research, 30, 2927-2933.
Barton, D.L., et al. (2011) A Double-Blind, Placebo-Controlled Trial of a Topical Treatment for Chemotherapy-Induced Peripheral Neuropathy: NCCTG Trial N06CA. Support Care Cancer, 19, 833-841. https://doi.org/10.1007/s00520-010-0911-0
Gewandter, J.S., et al. (2014) A Phase III Randomized, Placebo-Controlled Study of Topical Amitriptyline and Ketamine for Chemotherapy-Induced Peripheral Neuropathy (CIPN): A University of Rochester CCOP Study of 462 Cancer Survivors. Support Care Cancer, 22, 1807-1814. https://doi.org/10.1007/s00520-014-2158-7
Kautio, A.L., Haanpaa, M., Saarto, T. and Kalso, E. (2008) Amitriptyline in the Treatment of Chemotherapy-Induced Neuropathic Symptoms. Journal of Pain and Symptom Management, 35, 31-39. https://doi.org/10.1016/j.jpainsymman.2007.02.043